Clinical Trials Browser

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06333262 2026-01-21

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Phase 2 Recruiting

60 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07162181 2026-01-21

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Phase 2 Recruiting

13 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

70 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Phase 2 Recruiting

40 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05529069 2025-10-24

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase 2 Recruiting

30 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06812715 2025-08-06

PIPOZA

Phase 2 Recruiting

40 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06839872 2025-06-05

BOSS

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell